No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

Not Applicable

Recruiting

• Conditions: No-Reflow; Tirofiban; STEMI; Intracoronary
• Interventions: Drug: Intracoronary tirofiban; Drug: Saline 0.9%

• Registration Number: NCT06966674
• Lead Sponsor: Kafrelsheikh University

Brief Summary

This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.

Detailed Description

ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI).

The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI.

In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-04
• Study Start: 2025-05-12
• Study First Submitted QC: 2025-05-12
• Last Update Submitted: 2025-05-12
• Study First Posted: 2025-05-13
• Last Update Posted: 2025-05-13
• Primary Completion: 2025-10-01
• Study Completion: 2025-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age ≥ 18 years old.
• Both sexes.
• Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain >30 minutes with ST-segment elevation of >1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.

Exclusion Criteria

• Treatment with thrombolytic drugs in the previous 24 hours.
• Known malignancy.
• Thrombocytopenia.
• End-stage liver disease.
• Cardiogenic shock.
• Renal failure with glomerular filtration<30 ml/min.
• Contraindication for the use of tirofiban.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intracoronary tirofiban group	Intracoronary tirofiban	Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg)
Control group	Saline 0.9%	Patients will receive intracoronary saline 0.9% solution as a control group.

Primary Outcome Measures

Name	Time	Method
Blood stream	After treatment (Up to 15 minutes)	Blood stream in coronary artery before and after treatment, including Thrombolysis in Myocardial Infarction (TIMI) flow grade in IRAs, coronary blood flow will be calculated with TIMI frame count method.

Secondary Outcome Measures

Name	Time	Method
Incidence of major adverse cardiac events	After treatment (Up to 30 days)	Incidence of major adverse cardiac events were recorded.

Trial Locations

Locations (1)

Kafrelsheikh University; 🇪🇬 Kafr Ash Shaykh, Kafrelsheikh, Egypt